Patients with recurrent oesophageal squamous cell carcinoma (ESCC) after frontline fluoropyrimidine and platinum-based combinations generally receive docetaxel or paclitaxel, which are associated with poor long-term survival. According to data from the phase III ATTRACTION-3 trial, reported at the ESMO Congress 2019 and in the Lancet Oncology, nivolumab is a promising agent for these patients.
In this trial, patients with ESCC (including adenosquamous carcinomas) were randomly assigned to receive either nivolumab (n = 210) or standard second-line chemotherapy (n = 209). At 17.6 months, the median overall survival (OS) durations were 10.9 months and 8.4 months, respectively (HR 0.77; P = 0.02). For patients receiving nivolumab, the median OS duration was the same regardless of the level of tumour expression of PD-L1 (<1% or ≥1%). With chemotherapy, median OS durations were 9.3 months for patients harbouring tumours with <1% PD-L1 expression and 8.1 months for those with ≥1% PD-L1.
The objective response rate was 19% with nivolumab and 22% with chemotherapy. Overall, nivolumab was associated with inferior progression-free survival (median 1.7 months versus 3.4 months with chemotherapy; HR 1.08), but a superior median duration of response (6.9 months versus 3.9 months).
The incidence of grade ≥3 treatment-related adverse events was 18% with nivolumab and 64% with chemotherapy; two fatalities in the nivolumab group and three with chemotherapy were deemed to be treatment-related. Health-related quality of life was assessed with a three-level questionnaire (EQ-5D-3L), with results favouring nivolumab over chemotherapy.
In July 2019, the FDA approved pembrolizumab for patients with advanced-stage ESCC expressing PD-L1 (combined positive score (CPS) ≥10) in the second-line setting and beyond. This approval was based on the OS results of the KEYNOTE-181 trial: median 10.3 months with pembrolizumab versus 6.7 months with chemotherapy (HR 0.64). Whether nivolumab will be approved for this indication irrespective of PD-L1 expression remains to be seen.
References
Original article
Kato, K. et al. Lancet Oncol. https://doi.org/10.1016/S1470-2045(19)30626-6 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Nivolumab effective in oesophageal carcinoma. Nat Rev Clin Oncol 16, 723 (2019). https://doi.org/10.1038/s41571-019-0289-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0289-y